AI Article Synopsis
- Allogeneic hematopoietic stem cell transplantation is the most effective treatment for acute myeloid leukemia, particularly for patients in their first remission with a high risk of relapse.
- Reduced intensity transplantation makes the process safer, allowing older patients and those with other health issues to receive treatment.
- Improvements in histocompatibility testing and supportive care have enhanced the outcomes of this transplantation approach in tackling acute myeloid leukemia.
Article Abstract
Allogeneic hematopoietic stem cell transplantation provides the most powerful antileukemic effect in the treatment of acute myeloid leukemia. Due to its significant morbidity and mortality, it should be used in first remission patients whose relapse risk is substantial. Reduced intensity transplantation is safer and extends the application of early transplantation to older patients and those with comorbidities. In patients with advanced disease, allotransplantation provides a lower chance for cure, but is often the only curative treatment available. Advances in histocompatibility typing and supportive care have improved results of allogeneic transplantation in acute myeloid leukemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon.09.20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proton pump inhibitor effect on macrophage and neutrophil function: a systematic review.
Front Immunol
December 2024
College of Pharmacy, University of Houston, Houston, TX, United States.
Background: Proton pump inhibitors (PPIs) are one of the most used drugs worldwide. While generally considered safe, the usage of PPIs is associated with several adverse outcomes including acute infectious diseases. PPIs influence macrophage and neutrophil function although a systematic review has never been undertaken.
View Article and Find Full Text PDFKaleidoscopic Chloroma: An Unusual Case of Myeloid Sarcoma.
Cureus
December 2024
Radiology, Tata Main Hospital, Jamshedpur, IND.
We report a 37-year-old male patient who had nonbilious vomiting, no passage of flatus, and recurring abdominal pain. This patient had de novo intestinal myeloid sarcoma (MS), a rare and chameleonic presentation of acute leukemia of myeloid origin. The initial diagnostic evaluation suggested Koch's abdomen, and surgical excision of the bowel was performed with a clinical suspicion of Koch's or lymphoma.
View Article and Find Full Text PDFLow-Dose Acyclovir Reduces the Reactivation of Herpes Simplex and Varicella Zoster Viruses After Allogeneic Stem Cell Transplantation.
Cureus
December 2024
Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, USA.
Introduction: Reactivation of herpes simplex virus (HSV) and varicella zoster virus (VZV) is a potential complication following allogeneic stem cell transplantation (alloSCT). Since different doses and durations of acyclovir prophylaxis may be utilized across transplant centers, this study aimed to evaluate the effectiveness of a lower dose of acyclovir in preventing HSV and VZV reactivation in alloSCT recipients within our institution.
Methods: A retrospective chart review was conducted for patients who underwent alloSCT between April 2016 and May 2023.
Recent advances in the role of atypical cadherin FAT1 in tumorigenesis (Review).
Oncol Lett
March 2025
Department of Hematology, Shengli Oilfield Central Hospital, Dongying, Shandong 257000, P.R. China.
The FAT atypical cadherin 1 (FAT1) gene is the ortholog of the fat gene and encodes the protocadherin FAT1. FAT1 belongs to the cadherin superfamily, a group of full-length membrane proteins that contain cadherin-like repeats. In various types of human cancer, FAT1 is one of the most commonly mutated genes, and is considered to be an emerging cancer biomarker and a potential target for novel therapies.
View Article and Find Full Text PDFEvaluation of circ_0002232 and circ-vimentin gene expressions as valuable biomarkers in acute myeloid leukemia patients.
Mol Biol Rep
January 2025
Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Background And Aim: Acute myeloid leukemia (AML) is a remarkably complex malignancy; with considerable genetic, epigenetic, and phenotypic heterogenicity. Circ-RNAs are a novel class of non-coding RNA. They may influence leukemia development and offer exciting possibilities for targeted AML diagnosis and therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!